Monday, March 16, 2015

Valeant Pharmaceuticals International Inc said it increased its offer for Salix Pharmaceuticals Inc to $10.96 billion in cash, topping Endo International Plc's bid of $10.93 billion in cash and stock for the bowel drug maker.Salix has agreed to Valeant's new offer of $173 in cash, which is higher than its previous bid of $158 per share in cash made late last month, the two companies said in a joint statement on Monday.Endo on Wednesday offered to purchase Salix in a deal that was worth about $175 per share in cash and stock. As of Friday's close, Endo's offer was worth $172.56 per share.Salix shares rose 2.7 percent to $174 in premarket trading on Monday, while Valeant's U.S.-listed shares rose 1.2 percent to $199.80.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX remained unchanged at $197.43. In the past year, the shares have traded as low as $106.00 and as high as $206.84. On average, 3111320 shares of VRX exchange hands on a given day and today's volume is recorded at 1816.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 3.25% or $7.95/share to $252.29. In the past year, the shares have traded as low as $116.01 and as high as $263.91. On average, 417685 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 408224.

Please Donate

Article Archive

The reports on this site are for information purposes only and are not a recommendation for the purchase of securities. The information contained in these reports have been gathered from sources we believe to be reliable, however, we make no guarantee as to the accuracy or completeness to such information.